Evolent Health (EVH) Projected to Announce Quarterly Earnings on Thursday

Evolent Health (NYSE:EVH) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Evolent Health to announce earnings of ($0.01) per share and revenue of $597.6970 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. Evolent Health had a positive return on equity of 0.36% and a negative net margin of 26.29%.The firm had revenue of $496.25 million during the quarter, compared to analyst estimates of $534.00 million. During the same period last year, the company earned $0.06 EPS. Evolent Health’s quarterly revenue was up 2.6% compared to the same quarter last year. On average, analysts expect Evolent Health to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Stock Performance

Evolent Health stock opened at $3.11 on Wednesday. Evolent Health has a fifty-two week low of $2.10 and a fifty-two week high of $10.08. The company has a market capitalization of $349.48 million, a PE ratio of -0.65 and a beta of 0.79. The company has a 50 day moving average price of $4.77 and a 200-day moving average price of $3.72. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.32 and a current ratio of 1.32.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. CIBC Private Wealth Group LLC raised its position in Evolent Health by 4,000.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock worth $35,000 after buying an additional 4,000 shares during the last quarter. Strs Ohio purchased a new stake in shares of Evolent Health during the 1st quarter worth about $47,000. Headlands Technologies LLC purchased a new position in Evolent Health during the second quarter worth approximately $58,000. Quantbot Technologies LP acquired a new stake in Evolent Health in the 3rd quarter valued at $88,000. Finally, Caxton Associates LLP purchased a new stake in shares of Evolent Health during the third quarter worth about $93,000.

Analysts Set New Price Targets

EVH has been the subject of a number of recent research reports. Weiss Ratings downgraded shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 21st. Citigroup reaffirmed a “sell” rating and set a $6.75 target price (up from $5.50) on shares of Evolent Health in a research report on Thursday, July 23rd. Needham & Company LLC lifted their price target on Evolent Health from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Truist Financial lowered Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 price target for the company. in a research report on Tuesday, June 30th. Finally, Canaccord Genuity Group upped their price objective on Evolent Health from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.16.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.